Before joining Zydus, he was the President of Red Oak Sourcing, leading the company s "multibillion-dollar generic portfolio", overseeing all aspects of Red Oak s business. Patel, who has more than 20 years of experience in the generics and branded pharmaceutical marketplace, has also worked at Novartis Vaccines & Diagnostics and CVS Caremark, Zydus said.
A study analyzing data from Population Based Cancer Registries (PBCRs) in India found that approximately 52% of cervical cancer cases diagnosed between 2012 and 2015 survived. Ahmedabad s urban PBCR had the highest survival rate at 61.5%, while Tripura had the lowest at 31.6%.
Indian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for its CAR-T cell therapy NexCAR19. The therapy is the first of its kind to be developed in India and will be used to treat certain types of blood cancers. ImmunoACT intends to make the drug available to partner hospitals as soon as possible.
New Jersey-based Zydus Pharmaceuticals (USA) Inc. is recalling the affected lot due to "Failed Dissolution Specifications", the USFDA stated. The lot was produced at Ahmedabad and distributed in the US by Zydus Pharmaceuticals (USA) Inc, the US health regulator stated.
30% of people with sight loss experience a reduction in employment, with women, people in rural communities and ethnic minority groups among the groups most affected. 90% of vision loss is avoidable with early detection and treatment.